Oneness Biotech Co., Ltd. (TWO.4743) today announced that it has been selected for inclusion in the S&P Sustainability Yearbook 2024. It is also the only Taiwanese company in the industry group of Pharmaceuticals, Biotechnology & Life Sciences has been selected in the Sustainability Yearbook for two consecutive years. Showing that Oneness’ ESG efforts in implementing corporate governance, protecting environment and promoting social value has been recognized internationally.
The Yearbook is based on the scores resulting from S&P Global’s Corporate Sustainability Assessment (CSA), which is one of the most credible ESG evaluations globally. The Sustainability Yearbook 2024 covers 62 industries and over 9,400 companies around the world, only 759 companies are included in the 2024 Sustainability Yearbook. After achieving the distinction of being the first Taiwanese pharmaceutical company selected in the 2023 Sustainability Yearbook, Oneness Biotech Co., Ltd. has once again secured its position this year, joining the ranks of the 22 globally selected pharmaceutical enterprises.
According to the report, out of the 28 sub-items assessed, 16 ranked in the top 5%, with full scores in product stewardship, transparency and reporting, marketing practices, and occupational health and safety. Innovation management, product quality and recall management, environmental policy and management systems, materiality, business ethics, policy influence, and biodiversity ranked in the top 3% among the global pharmaceutical industry.
Huang Shan-Nei, Chairman of Oneness Biotech, emphasized that ESG is not only a corporate social responsibility but also a sustainable competitive advantage propelling the company's growth. The company acknowledges the dedicated efforts of all its employees in seamlessly incorporating sustainability into its operations. Having achieved the milestone of becoming the first Taiwanese pharmaceutical company selected in the Dow Jones Sustainability Index in December of the previous year, Oneness Biotech has once again earned a place in the Sustainability Yearbook 2024, underscoring its global leadership in sustainable performance.
Oneness has been dedicated to the development of new drugs in the chronic dermatology and immunology on the basis of our core value: science, integrity, and transparency. We aim to achieve the founding purpose of “Developing New Drugs and Caring for Life” by providing effective therapies to the patients with our science and innovation. At the same time, we are advocating for energy-saving policies and implementing low-carbon manufacturing practices for environmental sustainability, while also taking into account the interests of all stakeholders, to create shared value in the context of sustainability.
